Michinari Hieda

Michinari Hieda

Auto-generated profile, based on publicly available information

Michinari Hieda

Kyushu University Hospital

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
MHMichinari Hieda
Michinari Hieda
SSSatyam Sarma
Satyam Sarma
CHChristopher M. Hearon
Christopher M. Hearon
JMJames P. MacNamara
James P. MacNamara
KDKatrin A. Dias
Katrin A. Dias
BLBenjamin D. Levine
Benjamin D. Levine
Background: Individuals with left ventricular (LV) hypertrophy and elevated cardiac biomarkers in middle age are at increased risk for the development of heart failure with preserved ejection fraction. Prolonged exercise training reverses the LV stiffening associated with healthy but sedentary aging; however, whether it can also normalize LV myocardial stiffness in patients at high risk for heart failure with preserved ejection fraction is unknown. In a prospective, randomized controlled trial, we hypothesized that 1-year prolonged exercise training would reduce LV myocardial stiffness in patients with LV hypertrophy. Methods: Forty-six patients with LV hypertrophy (LV septum >11 mm) and elevated cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [>40 pg/mL] or high-sensitivity troponin T [>0.6 pg/mL]) were randomly assigned to either 1 year of high-intensity exercise training (n=30) or attention control (n=16). Right-heart catheterization and 3-dimensional echocardiography were performed while preload was manipulated using both lower body negative pressure and rapid saline infusion to define the LV end-diastolic pressure-volume relationship. A constant representing LV myocardial stiffness was calculated from the following: P=S×[Exp {a (V–V 0 )}–1], where “P” is transmural pressure (pulmonary capillary wedge pressure – right atrial pressure), “S” is the pressure asymptote of the curve, “V” is the LV end-diastolic volume index, “V 0 ” is equilibrium volume, and “a” is the constant that characterizes LV myocardial stiffness. Results: Thirty-one participants (exercise group [n=20]: 54±6 years, 65% male; and controls (n=11): 51±6 years, 55% male) completed the study. One year of exercise training increased max by 21% (baseline 26.0±5.3 to 1 year later 31.3±5.8 mL·min –1 ·kg –1 , P <0.0001, interaction P =0.0004), whereas there was no significant change in max in controls (baseline 24.6±3.4 to 1 year later 24.2±4.1 mL·min –1 ·kg –1 , P =0.986). LV myocardial stiffness was reduced (right and downward shift in the end-diastolic pressure-volume relationship; LV myocardial stiffness: baseline 0.062±0.020 to 1 year later 0.031±0.009), whereas there was no significant change in controls (baseline 0.061±0.033 to 1 year later 0.066±0.031, interaction P =0.001). Conclusions: In patients with LV hypertrophy and elevated cardiac biomarkers (stage B heart failure with preserved ejection fraction), 1 year of exercise training reduced LV myocardial stiffness. Thus, exercise training may provide protection against the future risk of heart failure with preserved ejection fraction in such patients. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03476785.

17 October 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
JMJames P. MacNamara
James P. MacNamara
KDKatrin A. Dias
Katrin A. Dias
CHChristopher M. Hearon
Christopher M. Hearon
EIErika Ivey
Erika Ivey
VDVincent A. Delgado
Vincent A. Delgado
BLBenjamin D. Levine
Benjamin D. Levine
Background: Moderate intensity exercise training (MIT) is safe and effective for patients with hypertrophic cardiomyopathy, yet the efficacy of high intensity training (HIT) remains unknown. This study aimed to compare the efficacy of HIT compared with MIT in patients with hypertrophic cardiomyopathy. Methods and Results: Patients with hypertrophic cardiomyopathy were randomized to either 5 months of MIT, or 1 month of MIT followed by 4 months of progressive HIT. Peak oxygen uptake (V˙O 2 ; Douglas bags), cardiac output (acetylene rebreathing), and arteriovenous oxygen difference (Fick equation) were measured before and after training. Left ventricular outflow gradient and volumes were measured by echocardiography. Fifteen patients completed training (MIT, n=8, age 52±7 years; HIT, n=7, age 42±8 years). Both HIT and MIT improved peak V˙O 2 by 1.3 mL/kg per min ( P =0.009). HIT (+1.5 mL/kg per min) had a slightly greater effect than MIT (+1.1 mL/kg per min) but with no statistical difference (group×exercise P =0.628). A greater augmentation of arteriovenous oxygen difference occurred with exercise (Δ1.6 mL/100 mL P =0.005). HIT increased left ventricular end‐diastolic volume (+17 mL, group×exercise P =0.015) compared with MIT. No serious arrhythmias or adverse cardiac events occurred. Conclusions: This randomized trial of exercise training in patients with hypertrophic cardiomyopathy demonstrated that both HIT and MIT improved fitness without clear superiority of either. Although the study was underpowered for safety outcomes, no serious adverse events occurred. Exercise training resulted in salutary peripheral and cardiac adaptations. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03335332.

1 September 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EHE. Ashley Hardin
E. Ashley Hardin
DSDouglas Stoller
Douglas Stoller
JLJustin Lawley
Justin Lawley
EHErin J. Howden
Erin J. Howden
MHMichinari Hieda
Michinari Hieda
BLBenjamin D. Levine
Benjamin D. Levine
Background: Accurate assessment of cardiac output is critical to the diagnosis and management of various cardiac disease states; however, clinical standards of direct Fick and thermodilution are invasive. Noninvasive alternatives, such as closed‐circuit acetylene (C 2 H 2 ) rebreathing, warrant validation. Methods and Results: We analyzed 10 clinical studies and all available cardiopulmonary stress tests performed in our laboratory that included a rebreathing method and direct Fick or thermodilution. Studies included healthy individuals and patients with clinical disease. Simultaneous cardiac output measurements were obtained under normovolemic, hypovolemic, and hypervolemic conditions, along with submaximal and maximal exercise. A total of 3198 measurements in 519 patients were analyzed (mean age, 59 years; 48% women). The C 2 H 2 method was more precise than thermodilution in healthy individuals with half the typical error (TE; 0.34 L/min [ r =0.92] and coefficient of variation, 7.2%) versus thermodilution (TE=0.67 [ r =0.70] and coefficient of variation, 13.2%). In healthy individuals during supine rest and upright exercise, C 2 H 2 correlated well with thermodilution (supine: r =0.84, TE=1.02; exercise: r =0.82, TE=2.36). In patients with clinical disease during supine rest, C 2 H 2 correlated with thermodilution ( r =0.85, TE=1.43). C 2 H 2 was similar to thermodilution and nitrous oxide (N 2 O) rebreathing technique compared with Fick in healthy adults (C 2 H 2 rest: r =0.85, TE=0.84; C 2 H 2 exercise: r =0.87, TE=2.39; thermodilution rest: r =0.72, TE=1.11; thermodilution exercise: r =0.73, TE=2.87; N 2 O rest: r =0.82, TE=0.94; N 2 O exercise: r =0.84, TE=2.18). The accuracy of the C 2 H 2 and N 2 O methods was excellent ( r =0.99, TE=0.58). Conclusions: The C 2 H 2 rebreathing method is more precise than, and as accurate as, the thermodilution method in a variety of patients, with accuracy similar to an N 2 O rebreathing method approved by the US Food and Drug Administration.

1 August 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
NANorman N. Aiad
Norman N. Aiad
CHChristopher Hearon
Christopher Hearon
MHMichinari Hieda
Michinari Hieda
KDKatrin Dias
Katrin Dias
BLBenjamin D. Levine
Benjamin D. Levine
SSSatyam Sarma
Satyam Sarma

19 April 2023 in JACC: Heart Failure
Verified
Journal Article
Closed access
SSSatyam Sarma
Satyam Sarma
JMJames P. MacNamara
James P. MacNamara
MHMichinari Hieda
Michinari Hieda
EHErin J. Howden
Erin J. Howden
JLJustin S. Lawley
Justin S. Lawley
BLBenjamin D. Levine
Benjamin D. Levine

15 October 2015 in International Journal of Cardiology
Verified
Journal Article
Open access
PDF file
Takuya WatanabeTakuya Watanabe
Takuya Watanabe
OSOsamu Seguchi
Osamu Seguchi
KNKunihiro Nishimura
Kunihiro Nishimura
TFTomoyuki Fujita
Tomoyuki Fujita
YMYoshihiro Murata
Yoshihiro Murata
TNTakeshi Nakatani
Takeshi Nakatani
Cardiac allograft vasculopathy (CAV) is the leading cause of late morbidity and mortality in heart transplant recipients, accounting for one-third of all-cause mortality at 5 years [ 1 x [1] Lund, L.H., Edwards, L.B., Kucheryavaya, A.Y., Dipchand, A.I., Benden, C., Christie, J.D. et al. International society for heart and lung transplantation, the registry of the international society for heart and lung transplantation: thirtieth official adult heart transplant report-2013; focus theme: age. J. Heart Lung Transplant. 2013; 32: 951–964 Abstract | Full Text | Full Text PDF | PubMed | Scopus (281) | Google Scholar See all References ] [1] . The pathophysiology of CAV is closely linked to both immunologic factors, such as alloreactive T-cell and antibody activation, and non-immunologic factors, including pre-transplant coronary artery disease, cytomegalovirus (CMV) infection, older age of the donor and recipient, recipient's conventional risk factor (e.g. hyperlipidemia, hypertension and diabetes mellitus) and ischemia/reperfusion injury [ 2 x [2] Rahmani, M., Cruz, R.P., Granville, D.J., and McManus, B.M. Allograft vasculopathy versus atherosclerosis. Circ. Res. 2006; 99: 801–815 Crossref | PubMed | Scopus (219) | Google Scholar See all References ] [2] . This complex etiology makes it difficult to prevent and suppress the development of CAV.